Home / Themes / GLP-1 Short '24: Professional Services
GLP-1 Short '24: Professional Services
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 6 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe thesis for GLP-1 drugs in the Professional Services sector is bearish as of Spring 2025. The increasing adoption of GLP-1 drugs for weight management is exp
Thesis
The thesis for GLP-1 drugs in the Professional Services sector is bearish as of Spring 2025. The increasing adoption of GLP-1 drugs for weight management is expected to lead to a healthier population, reducing healthcare costs and medical claims. This trend will likely impact companies like NSP, TNET, and RHI, which specialize in employee benefits and workforce solutions, by reducing the demand for their services centered around managing high healthcare costs.
Bull case
The widespread use of GLP-1 drugs is projected to lower obesity rates, subsequently decreasing healthcare costs and demand for employee benefit management services.
Companies specializing in providing health-related benefits may face pressure as healthier employees require fewer health interventions, impacting revenue.
As healthcare claims decrease, the traditional revenue model for benefits management and HR services could see a downturn, affecting professional services companies.
Bear case
The initial high cost of GLP-1 drugs could sustain demand for employee benefits management services as companies seek cost-effective ways to provide these medications to employees.
Companies offering health services might pivot to managing other wellness programs or preventative health measures, sustaining their relevance and revenue streams.
A potential regulatory push for insurance coverage of GLP-1 drugs could create opportunities for professional services firms to facilitate these transitions for employers.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| GLP-1 Prescription Volumes | Monthly | Adoption rate and market penetration of GLP-1 drugs | Google_Sheets |
| Healthcare Cost Index | Quarterly | Trends in overall healthcare expenses | Google_Sheets |
| Employee Benefits Spending | Quarterly | Changes in company spending on employee benefits | Google_Sheets |
Constituents
- MRSHT3· no notes yet
- NSPT3· no notes yet
- PAYXT3· no notes yet
- RHIT3· no notes yet
- TNETT3· no notes yet
- WTWT3· no notes yet